<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783808</url>
  </required_header>
  <id_info>
    <org_study_id>Ambox-2012-MEUP</org_study_id>
    <secondary_id>Uppsala University</secondary_id>
    <nct_id>NCT01783808</nct_id>
  </id_info>
  <brief_title>Intervention Study to Investigate Supplemental Oxygen in COPD</brief_title>
  <official_title>Effects on Exercise Capacity, Physical Activity and Quality of Life Using Ambulatory Oxygen in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Desaturate Only During Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the effects on exercise capacity, physical activity,&#xD;
      inflammatory markers and quality of life of supplemental ambulatory oxygen, to be used during&#xD;
      physical activity, in patients with COPD who are normoxic at rest but hypoxemic during a&#xD;
      six-min walk test.&#xD;
&#xD;
      Our hypothesis is that if patients are able to use supplemental oxygen they will be more&#xD;
      physically active and thereby improve health related quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design The study will employ a parallel design for 6 months including 144 patients (72&#xD;
      patients/group). Patients will be randomized to intervention or control group. The&#xD;
      intervention comprises supplemental oxygen to be used during physical activity for 6 months.&#xD;
      The control group will receive the same physical activity instructions as the intervention&#xD;
      group during the 6 months, but they will not be able to use supplemental oxygen during&#xD;
      physical activity.&#xD;
&#xD;
      The study will be a prospective, randomized, single-blind multi-centre intervention study&#xD;
      with an intention to treat design (last value carry over). Inclusion will continue until 144&#xD;
      patients have fulfilled the 6 months. Patients will be tested at baseline and after 6 months.&#xD;
      There will also be a follow-up after 12 months comprising questionnaires. The study will&#xD;
      include centers in Sweden Norway, Finland, and Estonia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six-minute walk test</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>The patient is supposed to walk as long as possible during six minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical activity level</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Physical activity will be measured with an activity monitor (accelerometer) and by a questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Change from baseline to six months</time_frame>
    <description>EuroQol five-dimension questionnaire, St Georges Respiratory Questionnaire, Hospital Anxiety and Depression Scale, COPD Assessment Test, Medical Research Council scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>C-reactive protein, Leucocytes, Thrombocytes, Erythrocytes, Hemoglobin</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>COPD</condition>
  <condition>Physical Activity</condition>
  <condition>Sedentary</condition>
  <arm_group>
    <arm_group_label>Supplemental oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.&#xD;
In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will not get supplemental oxygen during physical activity but they will get the same physical activity intervention as the intervention group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supplemental oxygen</intervention_name>
    <description>Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.&#xD;
In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used.</description>
    <arm_group_label>Supplemental oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD, Arterial Oxygen Saturation &gt; 8 kilopascal at rest&#xD;
&#xD;
          -  Oxygen Saturation ≤ 88% and a fall in Oxygen Saturation ≥ 4% during a six-minute walk&#xD;
             test in ambient air&#xD;
&#xD;
          -  No exacerbation within 4 weeks prior to the study&#xD;
&#xD;
          -  Post-bronchodilator forced expiratory volume at one second &lt; 80% predicted and forced&#xD;
             expiratory volume at one second /Vital capacity &lt; 0.7&#xD;
&#xD;
          -  Oxygen Saturation ≥ 92 % during a walk test in self-selected pace with supplemental&#xD;
             oxygen. Patients should use supplemental oxygen 10 minutes before the test starts.&#xD;
&#xD;
          -  Non-smoker (smoke free for ≥ 6 months)&#xD;
&#xD;
          -  Interest in being physically active&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Arterial carbon dioxide &gt; 6.5 kilopascal at rest&#xD;
&#xD;
          -  Orthopedic, neurologic or mental impairments that would limit physical activity&#xD;
&#xD;
          -  Neoplastic disease that is anticipated to influence survival&#xD;
&#xD;
          -  Patients exercising with supplemental oxygen&#xD;
&#xD;
          -  Long-term oxygen therapy&#xD;
&#xD;
          -  Patients with arterial auricular fibrillation and/or heart disease that might hinder&#xD;
             physical activity as judged by the physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christer Janson, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medical Sciences, Uppsala University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margareta I Emtner, PhD</last_name>
    <phone>+46184714761</phone>
    <email>margareta.emtner@neuro.uu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Wadell, PhD</last_name>
    <phone>+4690786 9887</phone>
    <email>karin.wadell@physiother.umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margareta I Emtner, PhD</last_name>
      <phone>+46184714761</phone>
      <email>margareta.emtner@neuro.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Christer Janson, Professor</last_name>
      <phone>+46186114115</phone>
      <email>christer.janson@medsci.uu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Margareta I Emtner, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Margareta Emtner</investigator_full_name>
    <investigator_title>PhD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Physical capacity</keyword>
  <keyword>Physical activity</keyword>
  <keyword>Inflammatory markers</keyword>
  <keyword>Health related quality of life</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

